Lupus

Overview

Systemic lupus erythematosus (SLE), usually called lupus, is a chronic autoimmune disease in which the immune system mistakenly attacks the body’s own tissues. It can cause unpredictable periods of inflammation (“flares”) and remission, affecting the skin, joints, blood cells, kidneys, heart, lungs, and brain; kidney inflammation, called lupus nephritis, is among its most serious complications. NIAMS lupus overview Women develop lupus about nine times as often as men, although anyone can be affected. NIAMS lupus overview

Prognosis has improved greatly: NIH materials report that approximately 97% of people with lupus survive at least five years after diagnosis and 90% survive at least 10 years, but outcomes vary substantially with organ involvement, access to specialist care, and treatment response. NIH Action Plan for Lupus Research There is currently no approved cure. Standard care aims to prevent flares and irreversible organ damage using hydroxychloroquine for most patients, carefully minimized corticosteroids, and—when needed—immunosuppressive drugs or biologics such as mycophenolate, cyclophosphamide, belimumab, anifrolumab, or rituximab for refractory disease. EULAR 2023 management recommendations

Scope of Recent Research (2020–present)

Since 2020, lupus research has increasingly focused on whether the autoimmune system can be durably “reset,” rather than merely suppressed. The dominant curative questions are whether profound removal of disease-driving B cells and antibody-producing plasma cells can produce lasting, treatment-free remission; whether this can be done safely and at scale; and how molecular biomarkers can identify the people most likely to benefit. Early clinical results are unusually promising for engineered cellular therapies, but they remain based largely on small, uncontrolled studies in severely treatment-resistant patients rather than definitive randomized trials. CD19 CAR-T case series

Major Breakthroughs and Emerging Therapies

The leading potential disease-reset strategy is CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T therapy takes a patient’s own T cells, engineers them to recognize a target, expands them, and infuses them back after chemotherapy that temporarily reduces existing immune cells. In lupus, CD19 CAR-T cells are intended to eliminate broad populations of B cells, including cells that can mature into autoantibody-producing cells. A 2022 compassionate-use study treated five young people with severe, drug-refractory SLE; all entered remission after a single infusion and discontinued lupus immunosuppression during the reported follow-up. Anti-CD19 CAR-T in refractory SLE

Follow-up evidence strengthened the signal while also underscoring its preliminary nature. In a 2024 case series, all eight participants with severe SLE achieved DORIS remission—a stringent internationally developed remission definition—after one CD19 CAR-T infusion; immunosuppressive therapy was stopped in all 15 participants across the lupus, myositis, and systemic-sclerosis groups. Median follow-up was 15 months, B cells eventually returned after a mean of 112 days, and the study reported mostly low-grade cytokine-release syndrome, although one participant developed pneumonia requiring hospitalization. CD19 CAR-T case series These findings support the hypothesis that newly regenerated B cells may return in a less self-reactive state, but they do not yet establish a permanent cure. CD19 CAR-T case series

A related strategy attempts to remove both CD19-positive B cells and longer-lived plasma cells. Dual CD19/BCMA CAR-T therapy adds B-cell maturation antigen (BCMA), a target expressed on plasma cells that can continue producing autoantibodies after conventional B-cell depletion. In a phase 1 open-label study, 12 people with refractory SLE received combined CD19- and BCMA-directed CAR-T cells; disease activity fell rapidly, kidney function improved in 10 participants with lupus nephritis within 90 days, and two participants with both lymphoma and lupus had medication-free lupus remission reported through as long as 46 months. CD19/BCMA CAR-T phase 1 study

Another plasma-cell-directed approach uses daratumumab, an already approved anti-CD38 antibody that depletes antibody-secreting cells rather than genetically engineering T cells. In the open-label phase 2 DARALUP study at Charité–Universitätsmedizin Berlin, 10 women with active SLE despite multiple prior treatments received eight weekly injections; median SLEDAI-2K disease-activity scores fell from 12 at baseline to 4 at week 12 and remained improved through week 36. DARALUP phase 2 study This is an important proof of concept for targeting persistent autoantibody production, but it is better described as a potentially powerful disease-modifying treatment than a demonstrated cure. DARALUP phase 2 study

Earlier-stage research is pursuing antigen-specific immune tolerance: teaching the immune system not to attack self while preserving ordinary infection defense. In one mouse study, biodegradable polymer nanoparticles carrying dexamethasone were delivered to dendritic cells, immune cells that help direct T-cell responses; the treatment increased regulatory T cells and reduced lupus-like disease in Fcgr2b-deficient mice. Tolerogenic nanoparticles in lupus-prone mice This platform is preclinical, but it represents a conceptually attractive route toward a selective immune cure rather than broad immune ablation. Tolerogenic nanoparticles in lupus-prone mice

Clinical Trials and Experimental Approaches

Several CAR-T trials are now testing whether the early academic results can be reproduced in larger, multicenter studies. Cabaletta Bio sponsors RESET-SLE, a phase 1/2 study of autologous CD19 CAR-T therapy resecabtagene autoleucel (rese-cel; CABA-201) in active non-renal SLE and lupus nephritis; the registered study began in February 2024, plans to enroll 28 participants, and has an estimated primary-completion date of December 2029. RESET-SLE trial record Kyverna Therapeutics is studying its fully human CD19 CAR-T product, KYV-101, in the phase 1/2 KYSA-3 trial for refractory lupus nephritis. KYSA-3 trial record

Efforts to make cell therapy faster and more accessible include “off-the-shelf” donor-derived products. A registered early-phase study in China is evaluating umbilical-cord-blood-derived allogeneic CAR-T cells targeting both CD19 and BCMA in refractory SLE; the trial began in March 2025 and is designed to measure adverse events, remission, and maintenance of drug-free remission. Allogeneic CD19/BCMA CAR-T trial In parallel, the completed DARALUP phase 2 study tested daratumumab in 10 patients and found reductions in clinical disease activity and anti-double-stranded DNA antibodies, but its single-arm design and short follow-up prevent conclusions about durable cure. DARALUP phase 2 study

Methodologies and Scientific Approaches

Researchers are combining clinical disease measures with immune monitoring to determine whether a therapy has truly reset lupus. CAR-T studies track B-cell depletion and recovery, autoantibodies such as anti-double-stranded DNA, complement proteins C3 and C4, kidney protein loss, and validated outcomes including DORIS remission and the SLE Disease Activity Index. RESET-SLE trial record These measurements help distinguish short-term suppression from sustained clinical and immunologic remission after treatment has stopped. CD19 CAR-T case series

To address lupus heterogeneity, investigators also use single-cell RNA sequencing, which measures gene activity cell by cell. A large study analyzed more than 1.2 million blood immune cells from 162 people with lupus and 99 controls, identifying elevated type I interferon-stimulated gene activity, shifts in T-cell and monocyte populations, and molecular subgroups of lupus. Single-cell lupus molecular atlas Animal models, including lupus-prone mice, remain important for testing tolerance-inducing nanoparticles and other delivery systems before human studies. Tolerogenic nanoparticles in lupus-prone mice

Leading Institutions and Funding

Major academic leaders include Friedrich-Alexander-Universität Erlangen–Nürnberg and the University Hospital Erlangen, where the first modern CD19 CAR-T lupus studies were developed; Charité–Universitätsmedizin Berlin, which led the DARALUP daratumumab trial; and centers participating in multinational CAR-T studies. Anti-CD19 CAR-T in refractory SLE DARALUP phase 2 study Key commercial developers include Cabaletta Bio, advancing rese-cel in RESET-SLE, and Kyverna Therapeutics, advancing KYV-101 in refractory lupus nephritis. RESET-SLE trial record KYSA-3 trial record

Public and nonprofit funding remains central because cure-oriented studies require specialized cell-manufacturing and long follow-up. NIH reported estimated lupus research support of $148 million for fiscal year 2025, while noting that its categorical totals are estimates rather than disease-specific budget lines. NIH categorical spending report The Lupus Research Alliance has created a targeted program for engineered cell therapies that offers up to $300,000 over two years for preclinical work and up to $600,000 over two years for ancillary studies linked to clinical trials; its Global Team Science Award provides up to $3 million over three years. Lupus Research Alliance funding programs

Strengths, Limitations, and Challenges

The strongest recent evidence is the consistency of deep remission signals after CD19-directed cellular therapy in people whose lupus had not responded to multiple standard treatments. CD19 CAR-T case series The apparent ability of some patients to remain well after B cells return is particularly important because it suggests more than temporary depletion. CD19 CAR-T case series Dual CD19/BCMA targeting may further address long-lived plasma cells, which are a plausible source of persistent autoantibodies. CD19/BCMA CAR-T phase 1 study

However, the evidence base is still small, selected, and mostly uncontrolled. CAR-T treatment generally requires immune-depleting chemotherapy and can cause cytokine-release syndrome, infections, low blood counts, and neurologic toxicity; long-term risks, relapse patterns, fertility implications, vaccine responses, and the durability of remission remain incompletely defined in lupus. CD19 CAR-T case series Autologous CAR-T also requires individualized cell collection and manufacturing, while donor-derived approaches must demonstrate that they can avoid rejection and other immune complications. Allogeneic CD19/BCMA CAR-T trial Finally, lupus is biologically diverse, so a treatment that appears curative for antibody-driven disease may not work equally well for interferon-dominant, kidney-predominant, neurologic, or other molecular subtypes. Single-cell lupus molecular atlas

Outlook and Future Directions

As of August 8, 2026, lupus is not curable in routine clinical practice, but the field has moved closer to a plausible disease-reset therapy than at any earlier point. The most important milestones to watch are reproducible drug-free remission in larger multicenter CAR-T trials; multi-year follow-up after B-cell reconstitution; rigorous safety data; evidence that cell therapy prevents kidney damage and other irreversible organ injury; and scalable approaches that reduce dependence on individualized manufacturing and intensive chemotherapy. RESET-SLE trial record KYSA-3 trial record

References

• NIAMS lupus overview — National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2026.
• NIH Action Plan for Lupus Research — National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2026.
• EULAR 2023 management recommendations — Fanouriakis et al., 2023.
• Anti-CD19 CAR-T in refractory SLE — Mackensen et al., 2022.
• CD19 CAR-T case series — Müller et al., 2024.
• CD19/BCMA CAR-T phase 1 study — Wang et al., 2024.
• DARALUP phase 2 study — Alexander et al., 2026.
• Tolerogenic nanoparticles in lupus-prone mice — Charoensuk et al., 2023.
• RESET-SLE trial record — ClinicalTrials.gov, 2026.
• KYSA-3 trial record — ClinicalTrials.gov, 2026.
• Allogeneic CD19/BCMA CAR-T trial — ClinicalTrials.gov, 2026.
• Single-cell lupus molecular atlas — Perez et al., 2022.
• NIH categorical spending report — National Institutes of Health, 2026.
• Lupus Research Alliance funding programs — Lupus Research Alliance, 2026.